Skip to main content

Table 1 Clinical-pathological correlations for TYMS gene expression in NSCLC patients treated with pemetrexed

From: Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer

  

Total

TYMS high expression

TYMS low expression

 
  

n

n

%

n

%

P-value

Age (mean (range))

 

57 (32–79)

54 (32–79)

 

66 (60–78)

 

1

Gender

Male

40

26

65.0

14

35.0

0.419

Female

22

12

54.5

10

45.5

 

Smoking habit

Current smoker

24

18

75.0

6

25.0

0.056

Former smoker

22

14

63.6

8

36.4

 

Never smoker

16

6

37.5

10

62.5

 

Histology

Adenocarcinoma

49

27

55.1

22

44.9

0.071

NSCLC nos

7

7

100

0

0

 

Squamous cell carcinoma

6

4

66.7

2

33.3

 

ECOG performance status

ECOG0

27

19

70.4

8

29.6

0.392

ECOG1

32

17

53.1

15

46.9

 

ECOG2

3

2

66.7

1

33.3

 

Line of treatment

1st line

16

9

56.3

7

43.8

0.661

2nd line

14

10

71.4

4

28.6

 

3rd, further lines

32

19

59.4

13

40.6

 

Response

No

45

30

66.7

15

33.3

0.025

Yes

7

1

14.3

6

85.7

 

Not evaluatable

10

7

70.0

3

30.0

 

Progression

No

24

4

16.7

20

83.3

0.003

Yes

38

34

89.5

4

10.5